List of Excipients in Branded Drug TAMOXIFEN CITRATE

« Back to Dashboard

Generic Drugs Containing TAMOXIFEN CITRATE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	tamoxifen citrate	0378-0144	ANHYDROUS LACTOSE
Mylan Pharmaceuticals Inc	tamoxifen citrate	0378-0144	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	tamoxifen citrate	0378-0144	CROSPOVIDONE
Mylan Pharmaceuticals Inc	tamoxifen citrate	0378-0144	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	tamoxifen citrate	0378-0144	SILICON DIOXIDE
Mylan Pharmaceuticals Inc	tamoxifen citrate	0378-0144	SODIUM LAURYL SULFATE
Actavis Pharma Inc	tamoxifen citrate	0591-2472	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in TAMOXIFEN CITRATE?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
3	CARBOXYMETHYLCELLULOSE CALCIUM
10	CELLULOSE, MICROCRYSTALLINE
21	CROSCARMELLOSE SODIUM
3	CROSPOVIDONE
1	HYPROMELLOSE
14	HYPROMELLOSE 2910

Tamoxifen Citrate Excipient Strategy and Commercial Opportunities

Last updated: September 29, 2026

Tamoxifen citrate is a mature, low-cost oral oncology product with broad generic availability and no meaningful active-ingredient exclusivity barrier in the United States. Commercial opportunity is concentrated in differentiated dosage forms, excipient systems that improve manufacturing reliability, palatability, dosing access, and supply-chain resilience. The strongest near-term targets are oral liquids, pediatric and geriatric presentations, taste-masked tablets or granules, and robust direct-compression platforms.

What is the FDA status of tamoxifen citrate?

Tamoxifen citrate is an FDA-approved selective estrogen receptor modulator used for breast cancer treatment, adjuvant therapy, ductal carcinoma in situ risk reduction, and reduction of breast cancer incidence in high-risk patients. FDA-approved products include 10 mg and 20 mg tablets and the 10 mg/5 mL Soltamox oral solution.[1,2]

Attribute	Commercial status
Active ingredient	Tamoxifen citrate
Drug class	Selective estrogen receptor modulator
Primary route	Oral
Common strengths	10 mg and 20 mg tablets
Oral liquid	Soltamox, 10 mg/5 mL
FDA pathway for generics	Abbreviated New Drug Application
Reference product history	Nolvadex
Current market structure	Multiple generic manufacturers plus branded oral solution
Biosimilar exposure	None; tamoxifen citrate is a small molecule
Primary commercial issue	Price competition and dosage-form differentiation

Tamoxifen citrate is converted to active metabolites, including 4-hydroxytamoxifen and endoxifen. The drug is lipophilic and has limited aqueous solubility, which makes excipient selection relevant to dispersion, dissolution, content uniformity, and oral-liquid development.[1,3]

What patents protect tamoxifen citrate?

The original tamoxifen compound and early pharmaceutical patents expired decades ago. Tamoxifen citrate is therefore an established generic molecule rather than a protected innovator asset.

The U.S. market has no practical biosimilar risk because biosimilar legislation applies to biologics, not small-molecule drugs. Generic manufacturers compete through ANDAs, manufacturing economics, supply reliability, packaging, and dosage-form capabilities.

Exclusivity category	Tamoxifen citrate position
Active-ingredient patent	Expired
Original formulation exclusivity	Expired
New chemical entity exclusivity	Expired
Current branded oral-solution differentiation	Product-specific formulation and regulatory positioning
Biosimilar exclusivity	Not applicable
Paragraph IV significance	Limited for the legacy molecule; relevant only if a listed, unexpired patent is tied to a specific product
Orange Book relevance	Product and patent listings must be checked by reference product and dosage form

The FDA Orange Book remains the controlling source for listed patents and exclusivity associated with FDA-approved reference products.[4] A company assessing an ANDA or 505(b)(2) strategy should not assume that a legacy active ingredient has no patent issues. The relevant question is whether an unexpired patent is listed against the targeted reference product, strength, formulation, or method of use.

When does tamoxifen citrate lose exclusivity?

Tamoxifen citrate lost meaningful U.S. market exclusivity long ago. Generic tablets have been available for many years, and the principal commercial protections associated with the original Nolvadex program have expired.

The remaining commercial barriers are not conventional molecule patents. They include:

• FDA approval requirements for the proposed dosage form.
• Bioequivalence and dissolution performance.
• Stability of the citrate salt and finished product.
• Manufacturing control for low-dose tablets.
• Taste and viscosity management in oral liquids.
• Supply continuity for oncology customers.
• Potential formulation, device, or process patents attached to a new product.

A new formulation can create a separate intellectual-property position if it contains a novel excipient system, delivery architecture, manufacturing process, or clinically meaningful use. A routine substitution of lactose, microcrystalline cellulose, or a standard disintegrant is unlikely to provide strong patent protection by itself.

What excipients are used in tamoxifen citrate tablets?

Tablet excipients differ by manufacturer. Common functional classes include fillers, binders, disintegrants, lubricants, glidants, coating polymers, pigments, and opacifiers.

Representative tamoxifen citrate tablet labels identify combinations such as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hypromellose, titanium dioxide, and triacetin.[5] These ingredients are not universal across all suppliers and should not be treated as a single market formulation.

Functional need	Candidate excipient classes	Relevance to tamoxifen citrate
Bulking	Lactose, microcrystalline cellulose, mannitol	Supports low-dose tablet weight and content uniformity
Binding	Povidone, copovidone, hydroxypropyl cellulose	Improves granule strength and tablet robustness
Disintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid breakup and dissolution
Lubrication	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and sticking
Flow enhancement	Colloidal silicon dioxide	Helps powder flow and die filling
Film coating	Hypromellose, polyethylene glycol, titanium dioxide	Improves handling, appearance, and swallowing
Taste management	Film coats, ion-exchange resins, polymer barriers	Relevant to chewable, dispersible, and liquid products
Liquid solubilization	Cosolvents, surfactants, complexing agents	Needed for a stable and acceptable oral solution

A high-value formulation objective is to obtain acceptable dissolution without excessive surfactant or aggressive processing. Because tamoxifen citrate has low dose strength relative to tablet mass, blend uniformity and segregation control can be as important as solubility enhancement.

What excipient strategy is best for tamoxifen citrate tablets?

The most defensible tablet strategy is a conventional immediate-release platform optimized for manufacturability, dissolution, and global excipient acceptability.

Direct-compression strategy

A direct-compression formulation can reduce processing steps and lower manufacturing cost. A typical development screen would evaluate:

• Microcrystalline cellulose or spray-dried lactose for compactability.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Colloidal silicon dioxide for flow.
• Magnesium stearate or sodium stearyl fumarate for lubrication.
• Low-shear blending to limit segregation.
• Film coating for swallowability and light protection.

Direct compression is commercially attractive for generic suppliers because it reduces granulation energy, solvent exposure, and batch-cycle time. The main risks are poor flow, lubricant sensitivity, blend uniformity, and dissolution changes caused by overcompaction.

Wet-granulation strategy

Wet granulation can be preferred where the active blend has poor flow or unacceptable content-uniformity risk. Povidone or copovidone may improve granule strength. The tradeoff is greater process complexity and potential sensitivity to moisture, drying conditions, and residual solvent.

A wet-granulated product can support a more robust manufacturing process, but it may not provide a meaningful market advantage unless it produces demonstrably better stability, dissolution, or production yield.

Low-dose content-uniformity strategy

Tamoxifen citrate tablets contain a relatively small amount of active ingredient. Excipient selection should therefore support:

• Narrow particle-size distribution.
• Controlled premixing.
• Low segregation during transfer.
• Consistent die filling.
• Validated blend and content-uniformity sampling.
• Minimal electrostatic charging.

A co-processed excipient may offer a manufacturing advantage if it improves flow and compressibility without compromising dissolution. The commercial value lies in yield, reproducibility, and reduced deviation rates rather than in a broad patent moat.

What formulations are protected by tamoxifen citrate excipient technology?

Conventional tablets are difficult to protect strongly because many excipient combinations are predictable. More defensible opportunities are associated with specific performance outcomes.

Potentially protectable platforms include:

1. A stable, palatable oral solution with reduced alcohol or reduced propylene glycol.
2. A taste-masked multiparticulate product for patients unable to swallow tablets.
3. A dispersible or orally disintegrating dosage form with controlled tamoxifen release.
4. A solid-dispersion or amorphous formulation with demonstrably improved dissolution.
5. A pediatric formulation with validated dose flexibility and acceptable excipient exposure.
6. A formulation that improves stability under high-temperature or high-humidity conditions.
7. A tamoxifen product paired with a dose-measuring device that improves administration accuracy.

A patent application would need more than a list of standard excipients. Stronger claims would generally require defined concentration ranges, a measurable stability or dissolution result, a specific taste-masking architecture, or a manufacturing process that produces an unexpected technical effect.

What excipients are used in Soltamox oral solution?

Soltamox is an oral solution containing 10 mg of tamoxifen citrate per 5 mL. Its labeled inactive ingredients include glycerol, propylene glycol, sorbitol solution, povidone, polysorbate 80, citric acid, sodium citrate, saccharin sodium, and flavoring components.[2]

The product illustrates the main excipient challenges for liquid tamoxifen:

• Solubilizing a lipophilic active ingredient.
• Maintaining chemical and physical stability.
• Managing sweetness and aftertaste.
• Controlling viscosity and pourability.
• Limiting precipitation during storage.
• Providing accurate dosing across pediatric and adult use cases.
• Managing excipient exposure in patients with dietary or metabolic restrictions.

A competing oral liquid could differentiate through reduced sugar, lower solvent content, improved flavor, lower viscosity, preservative-free packaging, or a more convenient administration device. Any replacement for the established excipient system would require comparative stability, dissolution or solubilization, microbial-control, and palatability data.

What commercial opportunities exist for tamoxifen citrate excipients?

Pediatric and adolescent formulations

Tamoxifen is used in selected pediatric and adolescent oncology settings, although approved labeling and clinical practice must be distinguished. A liquid or dispersible product can address swallowing limitations and weight-based dosing. The opportunity is strongest where hospitals currently rely on extemporaneous compounding or manipulation of adult tablets.

A commercial product could offer:

• 1 mg/mL or 2 mg/mL dose flexibility.
• A calibrated oral syringe.
• Alcohol-reduced or alcohol-free formulation.
• Improved flavor and reduced bitterness.
• Stability data after opening.
• Unit-dose packaging for hospital use.

Geriatric and dysphagia products

Breast cancer treatment includes a substantial population of older adults. A smaller tablet, orally disintegrating tablet, dispersible granule, or low-viscosity liquid could improve administration for patients with dysphagia or complex medication regimens.

The regulatory value depends on whether the product can demonstrate bioequivalence or qualify for a 505(b)(2) pathway. A simple line extension may be commercially easier than a clinically differentiated product, but it is also more exposed to generic price competition.

Hospital and specialty-pharmacy supply

A dependable oral liquid may generate value through institutional contracts rather than retail pricing. Buyers may prioritize:

• Reliable availability.
• Unit-dose packaging.
• Reduced compounding labor.
• Barcode compatibility.
• Tamper-evident packaging.
• Simple storage.
• Accurate dosing devices.

Excipient suppliers can participate through formulation partnerships, premix systems, taste-masking technologies, or contract development rather than by selling a standalone commodity ingredient.

Global-market formulations

Excipients accepted in the United States, European Union, Japan, and emerging markets can reduce registration and supply complexity. A formulation that depends on region-specific colors, flavors, animal-derived ingredients, or restricted solvents can increase regulatory friction.

Mannitol, microcrystalline cellulose, povidone, crospovidone, hypromellose, and selected surfactants have broad use histories. Even so, each target market requires review of local pharmacopeial status, permitted daily exposure, labeling, and pediatric acceptability.

How does tamoxifen citrate compare with competing endocrine therapies?

Tamoxifen competes with aromatase inhibitors such as anastrozole, letrozole, and exemestane, as well as fulvestrant in selected treatment settings. These products have different formulation and excipient opportunities.

Product class	Typical dosage form	Excipient opportunity
Tamoxifen citrate	Tablet and oral solution	Taste masking, liquid dosing, low-dose uniformity
Anastrozole	Immediate-release tablet	Tablet robustness and global generic supply
Letrozole	Immediate-release tablet	Low-cost direct compression and packaging
Exemestane	Immediate-release tablet	Stability and film-coating systems
Fulvestrant	Injectable depot	Suspension, syringe, and device technology

Tamoxifen has a clearer liquid-formulation opportunity than most competing oral endocrine therapies because an FDA-approved oral solution already establishes clinical and regulatory precedent. Its mature generic status also makes cost-efficient excipient systems more important than premium delivery technologies.

What patent litigation and Paragraph IV risks affect tamoxifen citrate?

No current, market-defining patent litigation is associated with the original tamoxifen citrate molecule in the United States. Historical generic entry occurred after expiration of the original product protections.

Paragraph IV risk would arise if a new reference product or branded formulation listed an unexpired patent covering a formulation, method of use, or delivery system. A manufacturer launching a new oral liquid or modified dosage form should evaluate:

• Orange Book listings for the reference product.
• Formulation patents covering solvent and surfactant systems.
• Method-of-use patents tied to specific patient populations.
• Device patents covering the dosing system.
• Patent-term adjustment and pediatric exclusivity.
• Litigation exposure after ANDA certification.

A supplier supplying a conventional excipient does not ordinarily obtain product-level exclusivity. Its leverage is more likely to come from proprietary grades, technical support, supply agreements, or co-development arrangements.

What licensing deals are available in tamoxifen citrate?

The most realistic licensing structures involve formulation technology rather than the active ingredient. Commercial models include:

• Exclusive use of a taste-masking platform in oncology liquids.
• Joint development of a pediatric or dysphagia-friendly product.
• Supply-and-license agreements for a co-processed excipient.
• Contract manufacturing arrangements for oral solution.
• Regional rights for a differentiated formulation.
• Technology transfer to a generic pharmaceutical manufacturer.

A licensing target should have a measurable advantage, such as extended in-use stability, improved palatability, reduced solvent burden, or a validated manufacturing-cost reduction. A standard excipient blend without proprietary process control is unlikely to support substantial upfront economics.

What is the revenue exposure and generic launch outlook?

Tamoxifen citrate tablets are highly price-sensitive because several generic suppliers can manufacture the product. Revenue concentration is more defensible in:

• Branded oral solution.
• Hospital and specialty-pharmacy channels.
• Pediatric and dysphagia formulations.
• Shortage-resistant supply.
• Unit-dose and adherence-oriented packaging.
• International markets with limited local manufacturing.

A new generic tablet would face rapid price erosion unless it has a cost advantage, reliable supply, or a differentiated package. A new oral liquid may achieve better pricing, but its market size is narrower and development costs are higher.

The most credible launch scenarios are:

Launch scenario	Market attractiveness	Main risk
Conventional 10 mg/20 mg tablet	Low to moderate	Immediate generic price competition
Low-cost direct-compression tablet	Moderate	Limited product differentiation
Pediatric oral solution	Moderate to high niche value	Clinical adoption and reimbursement
Taste-masked dispersible product	Moderate	Bioequivalence and palatability evidence
Hospital unit-dose oral liquid	Moderate	Contract concentration
Novel modified-release product	Uncertain	Clinical and regulatory burden

How strong is the tamoxifen citrate patent estate?

The active-ingredient patent estate is weak because the molecule is long off patent. A new product’s patent strength would depend on the formulation and the evidence supporting non-obviousness.

IP component	Relative strength
Original tamoxifen molecule	None commercially relevant
Standard tablet excipients	Weak
Routine film coating	Weak
Specific liquid solvent system	Moderate if technically distinct
Taste-masking architecture	Moderate to strong if validated
Device-plus-formulation combination	Moderate
Novel pharmacokinetic profile	Potentially strong, but clinically expensive
Manufacturing process with measurable yield benefit	Moderate

Key Takeaways

• Tamoxifen citrate is a mature generic small molecule with expired core exclusivity.
• The main commercial opportunity is dosage-form differentiation, not conventional tablet innovation.
• Oral liquids, pediatric products, dysphagia-friendly formats, and hospital unit-dose presentations offer the strongest niche potential.
• Tablet development should prioritize content uniformity, flow, disintegration, dissolution, and low-cost manufacturing.
• Soltamox establishes a regulatory and commercial reference point for liquid tamoxifen formulations.
• Standard excipient substitutions are unlikely to create strong patent protection.
• Proprietary taste masking, stability improvement, dosing systems, and validated process benefits can support more defensible IP.
• Generic tablet launches face rapid price competition, while differentiated liquids may command better margins in narrower markets.
• Orange Book review remains necessary for any ANDA or 505(b)(2) strategy involving a listed reference product or new formulation.

FAQs

Can tamoxifen citrate be formulated as an oral suspension?

Yes. An oral suspension may be feasible, but it requires control of sedimentation, redispersibility, dose uniformity, particle size, microbial quality, and palatability. A solution is generally simpler for dose accuracy if the active can remain solubilized throughout shelf life.

Which excipient is most important for tamoxifen citrate dissolution?

No single excipient is universally decisive. Disintegrant selection, particle size, wetting, compression force, and surfactant use collectively influence dissolution. Crospovidone, croscarmellose sodium, and wetting agents are reasonable development candidates, subject to formulation testing.

Is tamoxifen citrate suitable for an orally disintegrating tablet?

Potentially. An orally disintegrating tablet could address dysphagia, but bitterness, dose loading, mechanical strength, friability, and rapid dissolution must be controlled. Taste masking is likely to be the central technical challenge.

Does tamoxifen citrate require a novel excipient for product differentiation?

No. A product can differentiate through a new combination or application of established excipients, a device, packaging, or a manufacturing process. A novel excipient would increase regulatory complexity and is not necessary for most commercial strategies.

Can an excipient supplier obtain patent protection around tamoxifen citrate?

Yes, but protection would generally need to cover a specific formulation, process, delivery system, or technical effect. A patent claiming only the use of a conventional excipient in a routine tamoxifen tablet would face substantial validity risk.

References

1. U.S. Food and Drug Administration. (2023). Tamoxifen citrate prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (2024). Soltamox (tamoxifen citrate) oral solution prescribing information. FDA labeling database.

3. National Center for Biotechnology Information. (2024). Tamoxifen citrate: PubChem compound summary. PubChem.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. DailyMed. (2024). Tamoxifen citrate tablet: product labeling and inactive ingredients. National Library of Medicine.